MRI Activity versus Relapses as Markers of Disease Activity in SPMS: Data from Adelphi Real-World MS Disease Specific Programme and The Phase 3 EXPAND Study

Gavin Giovannoni¹, Emma Houchen², Lukas Sobisek², Himanshu Karu³, Suzannah Ryan⁴, Eddie Jones⁵, Patricia Dominguez Castro², Vladimir Bezlyak⁴, Daniela Piani-Meier⁴, Virginia de las Heras⁴, Carol Lines⁴

Oral presentation: 010
Session S14: MS Therapeutics; April 4, 2022

¹Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom; ²Novartis Ireland Ltd., Dublin, Ireland; ³Novartis Healthcare Pvt. Ltd., Hyderabad, India; ⁴Novartis Pharma AG, Basel, Switzerland; ⁵Adelphi Real World, Manchester, United Kingdom

Presentation at the American Academy of Neurology (AAN) 2022, April 2-7, 2022
## Disclosures

<table>
<thead>
<tr>
<th>Author Name</th>
<th>Disclosures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gavin Giovannoni</td>
<td>Received compensation from AbbVie, Atara Bio, Biogen, Sanofi-Genzyme, Merck KGaA, Novartis, Roche, Actelion, Celgene, Roche, Medscape, Oxford Health Policy Forum, Neurology Academy, Peervoice, Elsevier and Bristows.</td>
</tr>
<tr>
<td>Eddie Jones</td>
<td>Employee of Adelphi Real World and his organization has received a subscription fee from Novartis to access some of the data reported in this study.</td>
</tr>
<tr>
<td>Emma Houchen, Lukas Sobisek, Himanshu Karu, Suzannah Ryan, Patricia Dominguez Castro, Vladimir Bezlyak, Daniela Piani-Meier, Virginia de las Heras, Carol Lines</td>
<td>Employees of Novartis.</td>
</tr>
</tbody>
</table>

**Funding source:** This study is supported by Novartis Pharma AG, Basel, Switzerland.

**Acknowledgments:** Editorial support was provided by Grace Jeong, PhD of Alphabet Health, New York, NY, USA and was funded by Novartis Pharmaceuticals Corporation. This presentation was developed in accordance with Good Publication Practice (GPP3) guidelines. Authors had full control of the content and made the final decision on all aspects of this presentation.
Multiple sclerosis (MS), considered a disease continuum, may progress from a relapsing-remitting to a secondary progressive course\(^1\)

People living with secondary progressive MS (SPMS) are often categorized as active (aSPMS) or non-active (naSPMS) based on the evidence of their disease activity;\(^1\) however, the relative contribution of MRI activity and/or relapses in defining disease activity in both the real world and clinical trial settings is not well understood.

Introduction and Objectives

Objectives

- To evaluate:
  - Adelphi Real World MS Disease Specific Programme (DSP): The real-world differences between aSPMS and naSPMS groups
  - The contribution of MRI activity and relapses in defining disease activity in people living with SPMS in real world (Adelphi Real World MS DSP) and clinical settings (EXPAND)
  - EXPAND Phase 3 trial: Whether participants in the placebo group categorized as naSPMS at baseline remain in the same category or can revert to aSPMS

MRI, magnetic resonance imaging.

Methods: Adelphi Real World MS DSP study design

- People living with SPMS (n=3580) were grouped into aSPMS (≥1 new lesion on the most recent MRI and/or ≥1 relapse in the past 12 months; n=1889) and naSPMS (no new lesion and no relapse in the past 12 months; n=665) cohorts.

- MRI activity, relapse status, disease characteristics and treatment were analyzed descriptively.

---

8 Adults with only one reported DMT per regimen (Age ≥18 years at index [the day of physician visit]). 9 Data were retrospectively collected in annual waves during the period of 1 January 2011 to 31 December 2019 and included in this study. In each wave the next 10 PLwMS visiting their physician were included in this study. All associated dates relate to the day of survey completion. Data were not collected between 2011 and 2012.

DSP, Disease Specific Programme; DMT, disease-modifying therapy; MS, multiple sclerosis; PLwMS, people living with MS; SPMS, secondary progressive MS.
Methods: EXPAND study design (Core part)

- Participants (N=1651) with ≥1 relapse in the 2 years prior to screening and/or ≥1 Gd+ T1 lesion at baseline on MRI were categorized as aSPMS (n=779); and those with no relapse in prior 2 years and with no Gd+ lesion on MRI at baseline were categorized as naSPMS (n=866).

- At baseline, participants in the placebo group (N=546) were categorized as aSPMS (n=263) or naSPMS (n=283). During the study, evidence of disease activity was assessed either by MRI (examined yearly) or relapses (examined whenever relapses occur at or outside visits). Here, we present the on-study data for confirmed relapses and MRI activity for naSPMS participants in the placebo group from EXPAND (Core part).

- No direct comparisons were made among groups from Adelphi Real World MS DSP and the EXPAND trial (Core part).

---

*aFive participants did not receive the study drug. One participant was excluded from all safety and efficacy analyses (no signed consent form was supplied at study start).

aSPMS, active SPMS; EDSS, Expanded Disability Status Scale; EoCP, end of Core part; Gd+, gadolinium-enhancing; MRI, magnetic resonance imaging; naSPMS, non-active SPMS; SPMS, secondary progressive multiple sclerosis.
Results: Characteristics of PLwMS and MRI utilization (Adelphi Real World MS DSP)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>aSPMS (N=1889)</th>
<th>naSPMS (N=665)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EDSS score in the past 12 months, mean (SD)</td>
<td>n=1463</td>
<td>n=806</td>
</tr>
<tr>
<td></td>
<td>4.6 (1.72)</td>
<td>5.2 (1.76)</td>
</tr>
<tr>
<td>Change in EDSS score in the past 12 months, mean (SD)</td>
<td>0.43 (0.56)</td>
<td>0.20 (0.49)</td>
</tr>
<tr>
<td>Proportion of PLwMS having moderate-to-severe disease based on the physician’s perception (%)&lt;sup&gt;a&lt;/sup&gt;</td>
<td>73.5</td>
<td>87.8</td>
</tr>
<tr>
<td>Number of PLwMS with MRI conducted in the past 12 months (% non-missing)</td>
<td>1657 (87.7)</td>
<td>390 (58.7)</td>
</tr>
<tr>
<td>Number of MRIs conducted in the past 12 months</td>
<td>1848</td>
<td>576</td>
</tr>
<tr>
<td>Number of MRI scans conducted per person in the past 12 months, mean (SD)</td>
<td>1.24 (0.77)</td>
<td>0.87 (0.78)</td>
</tr>
<tr>
<td>Proportion of PLwMS not on any DMT (%)</td>
<td>23.4</td>
<td>45.1</td>
</tr>
</tbody>
</table>

<sup>a</sup>All data related to disease severity or level of activity contained within the Adelphi Real World MS DSP have no clinical thresholds or requirements but are based entirely on each physician’s interpretation.

<sup>a</sup>SPMS, active SPMS; DSP, Disease Specific Programme; EDSS, Expanded Disability Status Scale; MRI, magnetic resonance imaging; naSPMS, non-active SPMS; SD, standard deviation.

- In the past 12 months, people living with MS (PLwMS) categorized as naSPMS (vs aSPMS) had a higher mean Expanded Disability Status Scale (EDSS) score and were less frequently monitored with MRI (lower proportion had undergone MRI, and less MRI scans were done per person).

- Higher proportions of PLwMS categorized as naSPMS (vs aSPMS) had moderate-to-severe disease (based on their physician’s perception) and were not on any disease-modifying therapy (DMT).
Results: Proportion of PLwMS categorized as aSPMS according to relapse or MRI activity\(^a\) or both (Adelphi Real World MS DSP)

- Of PLwMS categorized as aSPMS, activity was most commonly detected via MRI than relapse in the real world.

\(^a\)T1, T2 and gadolinium-enhancing lesions were assessed.

aSPMS, active SPMS; DSP, Disease Specific Programme; MRI, magnetic resonance imaging; MS, multiple sclerosis; PLwMS, people living with MS; SPMS, secondary progressive MS.
Results: MRI Activity is a More Sensitive Tool to Measure Disease Activity Than Relapses In the Clinical Trial Setting (EXPAND)

In participants categorized as naSPMS at baseline in the placebo group, disease activity was subsequently identified in >50%, with MRI being a more sensitive detection tool than relapses.

Changes in disease activity over time in participants with naSPMS in the placebo group

- >50% of naSPMS participants in the placebo group subsequently experienced on-study disease activity (confirmed relapse or MRI activity or both).

Proportion of naSPMS participants on placebo with on-study confirmed relapse or MRI activity or both

- Relapse only: 4.6% (n/m=13/283)
- MRI activity only: 41.8% (n/m=110/263)
- Both relapse and MRI activity: 9.2% (n/m=26/283)

\(^a\text{At least 1 Gd+ T1 lesion, or new or enlarging T2 lesion at any post-baseline scan.}\)

aSPMS, active SPMS; Gd+, gadolinium-enhancing; m, number of subjects with result available; MRI, magnetic resonance imaging; n, number of subjects with relapse or MRI activity; naSPMS, non-active SPMS; SPMS, secondary progressive MS.
Conclusions

- In both real-world and clinical trial settings, MRI activity appears to be a more sensitive tool to measure disease activity than relapses.
- In the Adelphi Real World MS DSP:
  - MRI utilization was much lower in the naSPMS cohort than in the aSPMS cohort.
  - Fewer MRIs in the naSPMS cohort reduced the chance of detecting disease activity.
  - Despite higher disease severity, a higher proportion of people living with naSPMS (vs aSPMS) were not on any DMT.
- Reduced MRI monitoring in people living with naSPMS in the real-world is a concern, which decreases the chance to detect and treat any new disease activity in this population.
- In the EXPAND trial, disease activity was subsequently identified in more than half of the participants categorized as naSPMS at baseline in the placebo group.
- These data highlight the difficulties in defining aSPMS and naSPMS reliably, and the potential negative implications of incorrectly defining patients as naSPMS, resulting in suboptimal management of people living with SPMS.

aSPMS, active secondary progressive multiple sclerosis; DSP, Disease Specific Programme; MRI, magnetic resonance imaging; MS, multiple sclerosis; naSPMS, non-active secondary progressive multiple sclerosis.